An Open-Label, Phase II Study of the Polo-like Kinase-1 (Plk-1) Inhibitor, BI 2536, in Patients with Relapsed Small Cell Lung Cancer (SCLC)

• Published in: Lung cancer (Amsterdam, Netherlands) Netherlands), 2017-02, Vol.104, p.126-130
• Main Authors: Awad, Mark M, Chu, Quincy S-C, Gandhi, Leena, Stephenson, Joe J, Govindan, Ramaswamy, Bradford, Daniel S, Bonomi, Philip D, Ellison, David M, Eaton, Keith D, Fritsch, Holger, Munzert, Gerd, Johnson, Bruce E, Socinski, Mark A
• Format: Article
• Language: English
• Subjects: Administration, Intravenous; Adult; Aged; BI 2536; Cell Cycle Proteins - adverse effects; Cell Cycle Proteins - antagonists & inhibitors; Cell Cycle Proteins - therapeutic use; Disease-Free Survival; Female; Hematology, Oncology and Palliative Medicine; Humans; Lung Neoplasms - drug therapy; Lung Neoplasms - pathology; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Plk-1 inhibition; Polo-like kinase; Polo-Like Kinase 1; Protein Serine-Threonine Kinases - adverse effects; Protein Serine-Threonine Kinases - antagonists & inhibitors; Protein Serine-Threonine Kinases - therapeutic use; Proto-Oncogene Proteins - adverse effects; Proto-Oncogene Proteins - antagonists & inhibitors; Proto-Oncogene Proteins - therapeutic use; Pteridines - administration & dosage; Pteridines - adverse effects; Pteridines - pharmacology; Pulmonary/Respiratory; Recurrence; Small cell lung cancer; Small Cell Lung Carcinoma - drug therapy; Small Cell Lung Carcinoma - pathology; Smoking - epidemiology; Treatment Failure; Treatment Outcome
• ISSN: 0169-5002; 1872-8332
• DOI: 10.1016/j.lungcan.2016.12.019

Highlights • BI 2536 inhibits polo-like kinase 1 (Plk-1), a critical regulator of the cell cycle. • Plk inhibitors prevent growth of several small cell lung cancer (SCLC) cell lines. • In this phase II study, BI 2536 was not effective for patients with relapsed SCLC